Journal of Clinical Oncology Podcast
By Journal of Clinical Oncology
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. Usually presented in conjunction with an original report and an editorial published on www.jco.org, the JCO podcasts enable readers to stay current on the latest research while placing the results into a clinically useful context.
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
|
1 |
The Combination of Bortezomib, Thalidomide, and Dexamethasone in Relapsed Multiple Myeloma | This podcast will provide a critical evaluation of the combination of bortezomib, thalidomide, and dexamethasone in relapsed multiple myeloma | 5/14/12 | Free | View In iTunes |
|
2 |
Personalized Therapy for Breast Cancer: Is It Really Happening? | This Podcast reviews and comments on the use of the National Comprehensive Cancer Network (NCCN) Breast Cancer Outcome Database to demonstrate the actual rollout of the use of gene expression profile (GEP) testing for women with hormone receptor positive, node negative breast cancer and the accompanying changes in breast cancer chemotherapy utilization | 5/9/12 | Free | View In iTunes |
|
3 |
Routine Second Pathology Review for Node-Negative Breast Cancer: What is Learned and What is the Effect on Patient Care? | This Podcast reviews the design and results of the present study by Kennecke et al. and provides perspective regarding the clinical significance of these findings. | 5/7/12 | Free | View In iTunes |
|
4 |
Pre-Operative Metformin in Early-Stage Breast Cancer | This podcast reviews the rationale behind evaluation of metformin as a potential anti-cancer agent in breast cancer and describes the findings of a recent window of opportunity trial looking at the impact of metformin upon proliferative indices in women with early breast cancer. | 5/7/12 | Free | View In iTunes |
|
5 |
Fulvestrant and Anastrozole in Combination: FACT or Fiction? | This podcast reviews the results of the FACT trial in the context of other ongoing and proposed studies of endocrine therapy combinations. | 4/30/12 | Free | View In iTunes |
|
6 |
A New Day Dawning for Hodgkin Lymphoma? | This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well. | 4/30/12 | Free | View In iTunes |
|
7 |
The German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow Up of 11 Years: Implications of Long Term Follow Up | In this study, the implications of long term follow up of the German Rectal Study on clinical practice and future trial design will be discussed. | 4/23/12 | Free | View In iTunes |
|
8 |
Carboplatin-Gemcitabine-Bevacizumab: Expanding Treatment Options for Recurrent Platinum Sensitive Epithelial Ovarian Cancer | Carboplatin-Gemcitabine-Bevacizumab represents an additional regimen to consider for management of recurrent platinum sensitive epithelial ovarian cancer, although it raises several questions regarding the role of bevacizumab in this disease setting. | 4/23/12 | Free | View In iTunes |
|
9 |
The Use of Adjuvant Therapy in Elderly Patients with Resected Non-Small Cell Lung Cancer (NSCLC) | This podcast discusses adjuvant therapy in elderly NSCLC patients. | 4/23/12 | Free | View In iTunes |
|
10 |
Management and Prevention of Pain Related to Treatment or Disease | The podcast highlights recent JCO articles that underscore the need for improved assessment and management of cancer and treatment-related symptoms. | 4/16/12 | Free | View In iTunes |
|
11 |
1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting | The CHER-LOB trial is one of several that has demonstrated that adding lapatinib to trastuzumab and chemotherapy improves on the rates of complete pathological response among women receiving neoadjuvant therapy for HER2 positive breast cancer. Because the relationship between pCR and long-term outcomes remains ambiguous, this regimen is not recommended for ordinary use. However, these findings are a powerful support to the hypothesis that dual-modality anti-HER2 therapy is a potent combination. | 4/9/12 | Free | View In iTunes |
|
12 |
Management of Low Stage Ovarian Clear Cell Carcinoma | A reflection on the problems clinicians face when making a decision on how best to advise patients regarding management of early clear cell carcinoma of the ovary. | 4/9/12 | Free | View In iTunes |
|
13 |
Surviving Childhood Cancer: Defining Risk of Poor Cardiac Outcomes in Early and Middle Adulthood | This podcast provides observations and commentary on the JCO article "High risk of symptomatic cardiac events in childhood cancer survivors. | 4/2/12 | Free | View In iTunes |
|
14 |
No Advantage to Combining Cetuximab with 5FU, Leucovorin, and Oxaliplatin in Metastatic Colorectal Cancer | This podcast reviews a negative phase III clinical trial of cetuximab combined with chemotherapy in first-line metastatic colorectal cancer and focuses on the interaction of targeted therapy combined with chemotherapy. | 4/2/12 | Free | View In iTunes |
|
15 |
Sorting Through Early Melanomas to Identify Those at Higher Risk for Metastases | This podcast partitions patients with early melanoma into those with very favorable features and compares them to those with a higher risk for dying of metastatic melanoma. | 3/12/12 | Free | View In iTunes |
|
16 |
Sedation for the Management of Refractory Suffering | Incorporating the information form Dr Marconi's systematic review on the question "Does sedation at the end of life hasten death", I will provide useful guidance regarding how to discuss this issues with patients and their families. | 3/12/12 | Free | View In iTunes |
|
17 |
The Role of the Estrogen Receptor (ER) in Selecting Women, Diagnosed with DCIS for Adjuvant Therapy with Tamoxifen | This podcast describes the results from a subgroup of 732 women in the NSABP B-24 trial for the treatment of DCIS, where ER status was available, and describes how this can be used as a predictive test for response to adjuvant tamoxifen. | 3/5/12 | Free | View In iTunes |
|
18 |
How Cooperative Group Trials Impact Breast Cancer Care in United States | In this podcast, I will review a JCO article showing that the publication of CALGB C9343 trial results had little influence in practice patterns in the United States. I will discuss possible study-specific reasons for the lack in change of practice and explore the author’s implication that practitioners are more apt to adopt trials that add technologies and/or treatments compared to those that withhold therapies. | 3/5/12 | Free | View In iTunes |
|
19 |
What's Different Between One Colorectal Cancer and Another? It's All in the Genes | This podcast will discuss the current role of characterizing KRAS and BRAF in the management of colorectal cancer as well as a manuscript by Popovici and colleagues entitled "Identification of a poor prognosis BRAF-mutant-like population of colon cancer patients". In this manuscript, a molecular signature that characterizes a subgroup of colorectal cancers that behave like BRAF mutant tumors but do not have true BRAF mutations. The research moves beyond analysis of a single gene to characterize a tumor’s phenotype. | 3/5/12 | Free | View In iTunes |
|
20 |
Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormaliti | Patients with epidermal growth factor receptor (EGFR) gene mutations should receive EGFR tyrosine kinase inhibitors as 1st line therapy because they produce higher response rates, long progression free survival, reduced toxicity, improved symptom control and convenience of oral administration compared to chemotherapy doublets. | 2/28/12 | Free | View In iTunes |
|
21 |
Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers? | This JCO Podcast provides observations and commentary on the JCO article, "Randomized Phase III study comparing Paclitaxel Cisplatin Gemcitabine and Gemcitabine Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC 30987 Intergroup Study" by Joaquim Bellmunt et al. It provides my perspective that considers both statistical metrics and clinical outcomes in decision making for difficult to treat diseases. | 2/28/12 | Free | View In iTunes |
|
22 |
Early Stage Hodgkin Lymphoma -- How Much is Enough? | The management of patients with early stage Hodgkin lymphoma with unfavorable characteristics remains a topic for study. | 2/21/12 | Free | View In iTunes |
|
23 |
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia | This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels. | 2/21/12 | Free | View In iTunes |
|
24 |
Rethinking Our Use of CSFs in the Adjuvant Treatment of Women Who Have Estrogen Receptor Positive Cancers | When dose dense treatment was first described we were greatly enthusiastic for all women with breast cancer. As the experience has matured we now realize that the benefit is confined to women with ER negative cancers. We think it is time to question our use of CSFs and dose dense treatment in ER+ women based on 2 large trials and a conclusive meta-analysis. | 2/6/12 | Free | View In iTunes |
|
25 |
Recurrence and Survival Results of the GOG Lap2 Trial Confirm Safety of the Laparoscopic Approach to Surgical Staging and Treat | This podcast summarizes and discusses the outcome results of the GOG Lap2 trial which shows safety and clinical benefits of laparoscopy as compared to laparotomy for surgical staging and treatment of uterine cancer. | 1/30/12 | Free | View In iTunes |
|
26 |
"Anything You Can’t Do, I Can’t Do Either": Transplantation for High Risk AML | This is a commentary on a report from the EBMT demonstrating a higher relapse rate after allogeneic transplantation in AML patients with FLT3 ITD mutations. | 1/30/12 | Free | View In iTunes |
|
27 |
Safety and Efficacy of Sequential Adjuvant AI Therapy in ER Positive Breast Cancer | Long-term follow-up of efficacy and toxicity outcomes from the IES study of adjuvant aromatase inhibitor therapy in postmenopausal estrogen receptor positive breast cancer | 1/19/12 | Free | View In iTunes |
|
28 |
The Role of Ovarian Suppression for Fertility Preservation in Women Receiving Adjuvant Breast Cancer Chemotherapy | This podcast discusses the findings from the manuscript by Munster et al. regarding the use of ovarian suppression for fertility preservation in young women receiving adjuvant chemotherapy in the context of the current literature and future directions. | 1/9/12 | Free | View In iTunes |
|
29 |
Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients | The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors. | 1/9/12 | Free | View In iTunes |
|
30 |
The Importance of Tumor Biopsies for Analysis of Mechanisms of Response and Resistance in Prostate Cancer | This podcast will summarize the results of Efstathious et al and discuss possible mechanisms of resistance to castration based therapies in prostate cancer. | 12/19/11 | Free | View In iTunes |
|
31 |
Targeting the Angiopoietin-Tie2 Axis: A Promising Alternative Antiangiogenic Strategy for Epithelial Ovarian Cancer | Targeting the Angiopoietin-Tie2 axis is a promising alternative antiangiogenic strategy for the treatment of ovarian cancer that exhibits non-overlapping toxicities with inhibitors of the VEGF signaling pathway. | 12/19/11 | Free | View In iTunes |
|
32 |
Interim PET Scans in Diffuse Large B-Cell Lymphoma - More Than Another Biomarker? | This JCO Podcast provides observations and commentary on the JCO article, "Interim 18F-Fluorodeoxyglucose PET scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab" by Violaine Safar, et al. | 12/12/11 | Free | View In iTunes |
|
33 |
To Biopsy or Not to Biopsy? That is the Question | Biopsy of presumed metastatic breast cancer sites confirms the diagnosis in most women and alters therapy in 14% of women in a prospective study of 121 patients but its impact on outcome could not be reliably assessed. | 12/7/11 | Free | View In iTunes |
|
34 |
Disparities in Systemic Therapy for Breast Cancer | This podcast provides a commentary on the article by Wu et al that addresses disparities in systemic therapy for breast cancer. | 12/5/11 | Free | View In iTunes |
|
35 |
Adjusting for Treatment Cross-Over to Enable Analysis of Longer Term Outcomes in the MA.17 Trial | This Podcast reviews the background of the MA.17 trial, the results of the present manuscript and provides perspective on the current findings. | 11/28/11 | Free | View In iTunes |
|
36 |
Obesity and Colorectal Cancer: What's the Big Deal? | This podcast summarizes the findings of this JCO article and provides commentary on its applicability to practice. | 11/28/11 | Free | View In iTunes |
|
37 |
Combinations or Single Agents, Crossover or No Crossover: Considering Chemotherapy Strategies in the Multi-Chaptered Story of M | This podcast will critically review randomized phase III trial data examining the relative role of taxane monotherapy versus combination therapy as first-line treatment for HER2-negative metastatic breast cancer. | 11/14/11 | Free | View In iTunes |
|
38 |
Medical Oncologist Attitudes and Practice in Cancer Pain Management: A National Survey | This podcast discusses findings and implications of a recent survey study on attitudes and knowledge about cancer pain among medical oncologists | 11/14/11 | Free | View In iTunes |
|
39 |
Is a "Wait and See" Nonoperative Approach Justified after Chemoradiation for Rectal Cancer | This podcast will explore the feasibility of a nonoperative "wait and see" approach based on strict selection criteria in patients with locally advanced rectal cancer who achieve a complete clinical response after chemoradiation. | 11/7/11 | Free | View In iTunes |
|
40 |
Predictive Testing for BRCA1/2 Mutations: The Value of the "True"Negative | This podcast reviews the evidence that women testing negative for known familial BRCA1/2 mutations should adhere to current population breast cancer screening guidelines. | 10/31/11 | Free | View In iTunes |
|
41 |
Trastuzumab in the Adjuvant Setting - Sequential versus Concurrent: Will We Ever Know the Full Answer? | This Podcast provides observation and commentary on the JCO article "Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer". | 10/31/11 | Free | View In iTunes |
|
42 |
Adjuvant Treatment for Gastric Cancer: The Story Continues to Evolve | The mature results of a randomized comparison of S-1 versus observation in Japanese patients who have undergone a D2 resection for gastric cancer continue to show a significant survival benefit supporting the use of post-operative chemotherapy. | 10/17/11 | Free | View In iTunes |
|
43 |
Solving the Mystery of Recurrence in "Surgical Cures" for Early Non-Small Cell Lung Cancer | Podcast to review the article "Occult Metastases in Length Nodes Predict Survival In Resectable Non-Small Cell Lung Cancer: Report of the ACOSOG Z40040 Trial"" by Rusch et al. | 10/11/11 | Free | View In iTunes |
|
44 |
Comorbidity Data in Cooperative Trials: Feasible and Non Ignorable | The ATAC investigators collected comorbidity data on more than 9000 women and this article illustrates that it provides key information. | 10/11/11 | Free | View In iTunes |
|
45 |
Gender Equity and HPV-Associated Cancers in the United States | Rapid, dramatic shifts are ongoing in the population-level epidemiology of oropharynx cancer in the United States. | 9/29/11 | Free | View In iTunes |
|
46 |
Biomarker Selection for Maintenance Therapy in Advanced NSCLC | EGFR mutation is a predictive biomarker for maintenance erlotinib but its clinical application is limited. This podcast will explain why. | 9/29/11 | Free | View In iTunes |
|
47 |
Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia | This podcast summarizes the incidence and long-term outcome of osteonecrosis in a large prospective study of children treated for acute lymphhoblastic leukemia with the dexamethasone-based Dutch Childhood Oncology Group-ALL 9 Protocol. | 9/26/11 | Free | View In iTunes |
|
48 |
R-CHOP Chemotherapy as Upfront Treatment for Advanced Stage Follicular Non-Hodgkin Lymphoma | This podcast evaluates the context and reviews results of a randomized phase III trial comparing R-CHOP given at conventional 21 day intervals with R-CHOP given at 14 day intervals in patients with newly diagnosed follicular lymphoma. | 9/15/11 | Free | View In iTunes |
|
49 |
Venlafaxine and Clonidine for Treatment of Hot Flashes in Women with Breast Cancer | This podcast reviews the randomized double-blind placebo-controlled trial reported by Boekhout et al. that evaluates venlafaxine and clonidine for the treatment of hot flashes in women with breast cancer. | 9/12/11 | Free | View In iTunes |
|
50 |
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-Carriers: A Single Institution Exp | This podcast reviews the retrospective study by Arun et al. and discusses the lack of consensus regarding the relative chemosensitivity of breast cancers in mutation carriers and non-carriers as well as the optimal neoadjuvant chemotherapy for mutation carriers. | 8/31/11 | Free | View In iTunes |
|
51 |
Individualizing the Risk of Cardiovascular Mortality Following Androgen Deprivation Therapy for Prostate Cancer | Androgen deprivation therapy may not be associated with an increase in cardiovascular mortality in all men but only those with a prior cardiac event due to known coronary artery disease. | 8/15/11 | Free | View In iTunes |
|
52 |
High Risk Stage II Colon Cancer: What is the Role of Adjuvant Chemotherapy? | Stage II colon cancer with high risk factors is often treated with adjuvant therapy, however new data raise questions about the usefulness of this practice. | 7/21/11 | Free | View In iTunes |
|
53 |
Is Genotype Guided Tamoxifen Dosing Ready for Prime Time? | Commentary on a successful study in which genotype-guided tamoxifen dosing increased endoxifen concentrations in women with reduced CYP2D6 metabolism. | 7/18/11 | Free | View In iTunes |
|
54 |
Menopausal Hormone Therapy, Mammographic Density and Breast Cancer | Estrogen plus progestin and estrogen alone have different effects on mammographic density and breast cancer. | 6/23/11 | Free | View In iTunes |
|
55 |
The Growing Value of Risk Calculators for Men Considering Prostate Cancer Screening | This is a commentary on a recent study comparing two risk calculators for use in the setting of prostate cancer screening. | 6/20/11 | Free | View In iTunes |
|
56 |
Interpretation of the Biomarker Analysis and Final Overall Survival Results from IPASS | This podcast describes the analysis of the IPASS study population by EGFR mutation and EGFR FISH biomarker status, and also discusses the results and controversial analysis of overall survival from this trial. | 6/13/11 | Free | View In iTunes |
|
57 |
Curing Leukemia with a Single Drug | The use of arsenic trioxide as a single agent can produce long lasting remissions and a significant cure rate in patients with acute promyelocytic leukemia. | 6/6/11 | Free | View In iTunes |
|
58 |
Vaccination with an Autologous Idiotype Based Vaccine Following a Chemotherapy Induced Remission Holds Promise in the Treatment | In this podcast, results of randomized phase III clinical trial evaluating the effects of a patient specific idiotype tumor vaccine in patients with follicular lymphoma are summarized. The results demonstrate that idiotype vaccination may improve disease free survival in patients with follicular lymphoma who achieve a remission following chemotherapy. | 5/31/11 | Free | View In iTunes |
|
59 |
Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant C | The addition of oxaliplatin to fluorouracil-based neoadjvuant chemoradiation for locally advanced rectal cancer significantly increases toxicity but does not improve the pathologic complete response rate. | 5/23/11 | Free | View In iTunes |
|
60 |
MEK Inhibitors | The term targeted therapy is often used in cancer drug development. This podcast will discuss the study of a mEK inhibitor where the investigators actually looked at the impact on the target as well as whether the drug worked or did not work. | 5/16/11 | Free | View In iTunes |
|
61 |
Angiogenic Therapy in Breast Cancer: Axitinib with Chemotherapy Joins the Crowd | Commentary on a new small molecule inhibitor of angiogenesis in combination with chemotherapy for metastatic breast cancer. | 5/9/11 | Free | View In iTunes |
|
62 |
Advanced Radiation Therapy Technology Improves Survival in Lung Cancer | This SEER based study demonstrated that the advanced radiation therapy technique of three-dimensional conformal radiation therapy improved survival compared to the previously used method. | 5/2/11 | Free | View In iTunes |
|
63 |
The Dark Side of del(5q) MDS | This podcast will discuss the basic background of myelodysplastic syndromes and the clinical implications of TP53 mutations predicting outcomes in del(5q) MDS. | 4/25/11 | Free | View In iTunes |
|
64 |
Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer: Is it Ready for Prime Time? | This podcast describes the long term outcomes of patients treated with chemotherapy first, followed by either cystectomy or radiation therapy. It provides important information to practicing physicians who treat this disease in helping make decisions about the utility and effectiveness, as well as safety, of using chemotherapy for muscle invasive bladder cancer. | 4/18/11 | Free | View In iTunes |
|
65 |
Are Lung Cancers with BRAF Mutations Another Molecularly Defined Subgroup of Patients? | In this week's podcast, Dr. Jaine discusses the recent manuscript by Paik and colleagues evaluating BRAF mutations in patients with advanced lung cancer. The potential impact of BRAF mutations and outcomes with current therapies for lung cancer are discussed. | 4/11/11 | Free | View In iTunes |
|
66 |
Targeting the VEGF Receptor in Colon Cancer: Lessons Learned from Negative Trials | In this podcast, Dr. Neal J. Meropol provides his perspective on two large randomized studies of vatalanib in patients with metastatic colorectal cancer. | 4/4/11 | Free | View In iTunes |
|
67 |
The Performance of Breast MRI Screening Among Women with BRCA1/2 Mutations | Stage at diagnosis of breast cancer among women with BRCA1/2 mutations was available for women enrolled in a multi-modality screening protocol including breast MRI, and for women who were screened with routine mammography. There was a significant increase in early stage at diagnosis for women in the MRI protocol compared to those in the mammography alone group. | 3/28/11 | Free | View In iTunes |
|
68 |
Circulating Tumor Cells in Resectable Colorectal Cancer | This JCO Podcast provides observations and commentary on the JCO article, "Clinical Significance of Circulating Tumor Cells Including Cancer Stem-like Cells in Peripheral Blood for Recurrence and Prognosis in Colorectal Cancer Patients with Dukes stage B and C" by authors Hisae Iinuma, et al. | 3/24/11 | Free | View In iTunes |
|
69 |
Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Pat | This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al. | 3/17/11 | Free | View In iTunes |
|
70 |
RIBBON-1 Revisited | The randomized Phase III trial, Ribbon-1, was designed to examine whether the benefit of bevacizumab added to chemotherapy in metastatic breast cancer was specific to the taxanes or if the benefit could accrue regardless of the chemotherapy backbone. PFS was improved with the addition of bevacizumab to several cytotoxics, including capecitabine, taxanes, and anthracyclines. OS was not improved. This podcast reviews the salient design, results, and implications of this trial and puts it in context of other bevacizumab trials and controversies. | 3/17/11 | Free | View In iTunes |
|
71 |
Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Delay Skeletal Events in Patients | This podcast describes a phase III randomized study comparing the efficacy and toxicity of Denosumab with Zolendronic Acid for the prevention of skeletal complications in patients with malignancy. | 3/17/11 | Free | View In iTunes |
| Total: 71 Episodes |
Customer Reviews
Nice
Good platform
Listeners also subscribed to
- ASCO Audio Journal of Oncology In Advance Presentations
- Produced by Audio Medica for the American Society of Clinical Oncology
- View In iTunes
- Journal of Oncology Practice Podcast
- Journal of Oncology Practice
- View In iTunes
- Listen to The Lancet Oncology
- The Lancet Oncology
- View In iTunes
- Oncology Learning Center CME Podcasts
- Oncology Learning Center
- View In iTunes
- Free
- Category: Medicine
- Language: English
- © Copyright by the American Society of Clinical Oncology
